尽管季度亏损且内部抛售，分析师评级混合，Spyre Therapeutics股价上涨。 Spyre Therapeutics shares rose after mixed analyst ratings despite a quarterly loss and insider selling.

根据分析师混合评级,Syre Spyre治疗(SYRE)股份在星期五上升至42.08美元,比平均值高出4.27美元。 Spyre Therapeutics (SYRE) shares rose to $42.08 on Friday, up $4.27, on higher-than-average volume, following mixed analyst ratings. Wells Fargo将其价格目标提高到500美元,并给予“超重”评级,而花旗集团和JonesTrading的“买”评级分别为64美元和70美元。 Wells Fargo raised its price target to $50.00 with an “overweight” rating, while Citigroup and JonesTrading issued “buy” ratings with targets of $64.00 and $70.00, respectively. 股票有一致的“Buy”评级,平均目标是53.44美元。 The stock has a consensus “Buy” rating and an average target of $53.44. 该公司报告季度损失每股0.70美元,略低于估计数,预计全年损失为4.46美元。 The company reported a quarterly loss of $0.70 per share, slightly below estimates, with projected full-year losses of $4.46. 注意到内幕出售,包括CEO交易15 000股,价值32.80美元。 Insider selling was noted, including a CEO transaction of 15,000 shares at $32.80. 该公司以癌症免疫疗法为重点,市场上限为32.6亿美元,贝塔为3.15。 The firm, focused on cancer immunotherapies, has a market cap of $3.26 billion and a beta of 3.15.